Lv21
140 积分 2024-09-08 加入
ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor–Mutated Advanced Non–Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib
6天前
已关闭
Chemotherapy-Based Combination Regimens for Advanced EGFR-Mutant NSCLC After EGFR-TKI Failure: A Network Meta-Analysis
2个月前
已关闭
A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance – The ETOP 15-19 ABC-lung trial
2个月前
已完结
Efficacy of atezolizumab, bevacizumab, carboplatin, and paclitaxel for epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer after tyrosine kinase inhibitor failure
2个月前
已关闭
Osimertinib rechallenge in advanced EGFR non-small cell lung cancer patients
2个月前
已完结
Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC
2个月前
已完结
Results from a phase 1b study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein–overexpressing, EGFR-mutated locally advanced/metastatic non-small cell lung cancer (NSCLC) after progression on prior osimertinib
2个月前
已完结
Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The SPIRAL-STEP study
2个月前
已完结
Long-term Survival Case of SCLC Transformation After Osimertinib Resistance in EGFR-mutant NSCLC: Benefits from Chemo-immunotherapy Combined with Anti-angiogenic Therapy Followed by Osimertinib Rechallenge
2个月前
已完结
Amivantamab Plus Lazertinib in Patients With EGFR-mutant Non-small Cell Lung Cancer (NSCLC) After Progression on Osimertinib and Platinum-based Chemotherapy: Results From CHRYSALIS-2 Cohort A
2个月前
已完结
皖公网安备34019202002308
